# B7-H3 CAR-T for Recurrent or Refractory Glioblastoma

> **NCT04077866** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Glioblastoma
- Refractory Glioblastoma

## Interventions

- **DRUG:** Temozolomide
- **BIOLOGICAL:** B7-H3 CAR-T

## Key facts

- **NCT ID:** NCT04077866
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-12-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04077866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04077866, "B7-H3 CAR-T for Recurrent or Refractory Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04077866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*